{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:40:20Z","timestamp":1773218420573,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.atherosclerosis.2014.10.105","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T21:06:21Z","timestamp":1415135181000},"page":"829-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis"],"prefix":"10.1016","volume":"237","author":[{"given":"Baishali M.","family":"Ambegaonkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Tipping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam B.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-0099","authenticated-orcid":false,"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia \u2013 full report","volume":"8","author":"Grundy","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib4","first-page":"151","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"issue":"25 Suppl.\u00a02","key":"10.1016\/j.atherosclerosis.2014.10.105_bib7","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib12","first-page":"861924","article-title":"Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients","author":"Karalis","year":"2012","journal-title":"Cholesterol"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1185\/03007990903426811","article-title":"Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin","volume":"26","author":"Willey","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.03.2118","article-title":"LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice","volume":"122","author":"Rublee","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population","volume":"168","author":"Blazing","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe plus statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/VHRM.S49840","article-title":"Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy","volume":"9","author":"Foody","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-511X-11-18","article-title":"Ezetimibe\/simvastatin 10\/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study","volume":"11","author":"Hing Ling","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2009.02022.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy \u2013 the IN-CROSS study","volume":"63","author":"Farnier","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2009.10.029","article-title":"Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or\u00a0= 65 years of age (from the ZETia in the ELDerly [ZETELD] study)","volume":"106","author":"Zieve","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.amjcard.2013.08.031","article-title":"Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia","volume":"112","author":"Bays","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A\u00a0community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/030079905X382004","article-title":"LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia","volume":"21","author":"Brohet","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijcard.2005.01.022","article-title":"Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease","volume":"102","author":"Farnier","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1368-5031.2005.00565.x","article-title":"Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease","volume":"59","author":"Cruz-Fernandez","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib32","doi-asserted-by":"crossref","first-page":"227A","DOI":"10.1016\/S0735-1097(03)81639-X","article-title":"Coadministration of ezetimibe with simvastatin","volume":"41","author":"Dobs","year":"2003","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1463-1326.2004.00420.x","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients","volume":"7","author":"Gaudiani","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2008.09.075","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease","volume":"102","author":"Conard","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib36","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.amjcard.2008.09.076","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with up-titration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease","volume":"102","author":"Leiter","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1368-5031.2005.00714.x","article-title":"Lipid-altering efficacy of switching from atorvastatin 10 mg\/day to ezetimibe\/simvastatin 10\/20 mg\/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease","volume":"59","author":"Barrios","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1463-1326.2007.00725.x","article-title":"Efficacy of ezetimibe\/simvastatin 10\/20 and 10\/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus","volume":"9","author":"Constance","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1479164112465212","article-title":"A\u00a0comparison of efficacy and safety of an ezetimibe\/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease","volume":"10","author":"Rosen","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3310\/hta12210","article-title":"Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation","volume":"12","author":"Ara","year":"2008","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1476-511X-12-137","article-title":"Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes","volume":"12","author":"Torimoto","year":"2013","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1185\/030079908X273273","article-title":"The efficacy of statin monotherapy uptitration versus switching to ezetimibe\/simvastatin: results of the EASEGO study","volume":"24","author":"Roeters van Lennep","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib44","first-page":"S276","article-title":"Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting","volume":"13","author":"Harley","year":"2007","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.atherosclerosis.2014.10.105_bib45","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection","year":"2002","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014015603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014015603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:36:20Z","timestamp":1758155780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014015603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0021915014015603"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.105","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}